The PD-1 checkpoint inhibitor Opdivo® (nivolumab) is a new treatment option for patients with non-small cell lung cancer.
March 4, 2015
CRI's CEO Jill O'Donnell-Tormey, Ph.D., shares some of the latest news in cancer immunotherapy.
February 27, 2015
CRI scientists have contributed significantly to the immunological understanding and treatment of colorectal cancer.
February 26, 2015